Purdue announces expanded support for the Prescription Drug Safety course through an additional sponsorship in Tennessee STAMFORD, Conn. – August 20, 2019 — Purdue Pharma L.P. (“Purdue”), a founding member of the Prescription Drug Safety Network (“the Network”),...
Company to provide access to data and intellectual property STAMFORD, Conn./TULSA, Okla., August 15, 2019 – Purdue Pharma L.P. (“Purdue”) and the National Center for Wellness & Recovery (the “Center”) at Oklahoma State University...
News and Media STAMFORD, CT, July 2, 2019 — Purdue Pharma L.P. today announced that Julie Ducharme, BPharm, MSc, PhD will be joining the organization as Vice President and Chief Scientific Officer with accountability to help progress its existing pipeline and identify...
News and Media STAMFORD, Conn., June 18, 2019 – Purdue Pharma L.P. presented a poster describing an approach to the evaluation of opioid comparators when assessing the effectiveness of abuse-deterrent formulations (ADFs) of extended-release opioids at the College...
News and Media NAL1002 study will examine pharmacokinetics, safety and tolerability of nalmefene HCl Company will not profit from nalmefene HCl injection Stamford, Conn. – June 6, 2019 – Purdue Pharma L.P. today announced the initiation and first participant...
News and Media WOODCLIFF LAKE, N.J. and STAMFORD, Conn. – April 30, 2019 – Eisai Inc. and Purdue Pharma L.P. today announced that Eisai will buy out Purdue’s rights to the worldwide collaboration for the development and commercialization of lemborexant, an...
